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RTo the Editor: Circulating transforming growth factor (TGF)-
beta has received recent attention because it may potentially serve
as a biomarker for therapeutic monitoring of aortic remodeling
processes in patients with Marfan syndrome (1,2). TGF-beta and
its actions are regulated by the elastic protein fibrillin-1. TGF-beta
is bound in a complexed form to fibrillin-1, which, on pathogenic
insult, is disrupted to release and activate the TGF-beta molecule,
which in turn acts on vascular cells to induce aortic remodeling.
Mutation of fibrillin-1 leading to aberrant regulation of TGF-beta
is thought to be a central pathogenic mechanism of Marfan
syndrome (3). Recent discoveries that renin-angiotensin system
inhibitors directly act on dysregulation of TGF-beta to affect aortic
remodeling have opened up new therapeutic possibilities for this
disease (1,4).
Whether TGF-beta is increased in aortic conditions in the
non-Marfan adult, however, has remained unknown. Here, we
show that circulating TGF-beta levels are elevated in patients with
acute aortic dissection. Efforts have been made to develop diag-
nostic biomarkers of this disease because aortic dissection is a
catastrophic aortic disease with high mortality and morbidity that
requires immediate diagnosis and treatment. Aortic dissection and
rupture are also primary cardiovascular manifestations in patients
with Marfan syndrome who reach adolescence.
In 28 non-Marfan patients with acute aortic dissection defined
as being within 24 h of symptom onset, TGF-beta levels as
measured by a commercially available assay (TGF-beta 1 Quan-
tikine immunoassay, R&D Systems, Minneapolis, Minnesota)
showed elevations at 24.5  12.9 ng/ml (median 25.4 ng/ml) that
re approximately 5-fold elevations compared with normal controls
5.4  2.8 ng/ml) (5). When categorized according to dissection
ype, Stanford type A dissections showed approximately 2-fold
levations (p  0.01, nonparametric Mann-Whitney U test) in
ype A patients (28.5  14.7 ng/ml [n  20]; median 28.7 ng/ml)
ompared with type B dissections (14.4  6.1 ng/ml [n  8];
edian 14.6 ng/ml). Circulating TGF-beta levels were therefore
arkedly elevated in patients with type A dissections, which are
ften associated with a worse prognosis and require immediate
edical attention. Collectively, our findings, although preliminary,
uggest that circulating TGF-beta levels may also serve as a
otential biomarker of aortic disease in the non-Marfan adult.
Further questions that remain to be addressed are whether
irculating TGF-beta levels can be used to monitor remodeling
ynamics in aortic conditions such as aortic dissection and aneu-
ysms in the non-Marfan adult and whether they will be responsive
o pharmacological treatment. For example, whether circulatingGF-beta levels will serve as a reliable surrogate biomarker to
ssess aortic expansion in type B dissections that might predict the
eed for surgery and response to medication during the course of
reatment will need to be addressed. More sensitive assays may be
ecessary to allow accurate assessment as necessary for therapeutic
onitoring in the chronic phase of disease progression. Nonethe-
ess, we believe that circulating TGF-beta is a promising bio-
arker for potential use in diagnostic and therapeutic assessment
f aortic diseases.
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